Open tender · Germany · Contract notice
Open House Originale Rabattverträge 2025-04 - Emtricitabin/Tenofoviralafenamid/Rilpivirin (Odefsey(R))
Techniker Krankenkasse in Germany is inviting bids for “Open House Originale Rabattverträge 2025-04 - Emtricitabin/Tenofoviralafenamid/Rilpivirin (Odefsey(R))”. Bids close on 28 February 2027. To qualify, bidders need at least one similar completed work and Marketing Authorization (Zulassung).
The work
Conclusion of discount contracts for the drug combination Emtricitabin/Tenofoviralafenamid/Rilpivirin (Odefsey(R)) under the Open-House-Originale procedure.
- Must be a pharmaceutical entrepreneur as defined by § 4 Abs. 18 AMG
- Must have a valid marketing authorization for the drug combination
- Must have a seat in the EU/EEA
Key facts
- Contract period
- Max 24 months from 01.03.2025
What it takes to qualify
Worth a closer look
- Alle weiteren Informationen sind den Teilnahme- und Vertragsunterlagen zu entnehmen.
Experience
- At least 1 similar work — Pharmazeutischer Unternehmer i. S. d. § 4 Abs. 18 AMG regarding the specific drug combination
- Holding a valid marketing authorization for Emtricitabin/Tenofoviralafenamid/Rilpivirin (Odefsey(R))
Certifications and registrations
Marketing Authorization (Zulassung)Valid authorization for the specific drug combination per § 21 AMG
GST registration (optional)Not applicable for a German pharmaceutical tender under SGB V
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Eigenerklärung zur Zulassung und zum Unternehmen (Anlage 4 zum Vertrag)Self-declaration of status as a pharmaceutical entrepreneur and valid authorization